Pierre Miossec: IL-17 from discovery to targeting: with focus on IL-17 family members

Friday, 13 May 2022 || Time: 12:00 - 13:00

CIL-17 was identified in 1995 as a T cell derived cytokine with effects on inflammation and matrix destruction. Its inhibition reduced the production and function of inflammatory mediators, the basis for its targeting in various inflammatory diseases. In addition to these local effects, IL-17 has systemic effects on vessels, liver, muscle among many targets. In 2001, sequence analyses identified proteins with various degrees of homology with that of IL-17, then renamed IL-17A.
These proteins were included in the IL-17 family composed of 6 members, including IL-17F with a 60 % homology and IL-17E/IL-25 with only 19% homology. Although IL-17F is less potent than IL-17A, tissue sections show more IL-17F positive cells, a strong argument for its targeting. IL-17A and F functions are regulated by IL-17E/ IL-25, which acts as a receptor antagonist. These results have been recently applied to the clinic with the targeting of both IL-17A and F, which appears more active than that of IL-17A alone.

Campus-Happy Hour after the Seminar!
Stay and network with your Campus-Colleagues. Especially for PostDoc Fellows and doctoral students!

Kontakt
Dr. Elke Luger
luger@drfz.de
Tel.: 030 28460 737